Teva Pharmaceutical (TEVA) Receives FDA Approval for Venlafaxine Hydrochloride Tablets
Down)
Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced that the U.S. Food and Drug Administration (FDA) has granted final approval for the Company's Abbreviated New Drug Application for Venlafaxine Hydrochloride Tablets, 25 mg, 37.5 mg, 50 mg, 75 mg and 100 mg. Shipment of this product will begin immediately.
Teva's Venlafaxine HCl Tablets are the AB-rated generic equivalent of Wyeth's Effexor Tablets, a product indicated for the treatment of major depressive disorder.
The brand product has annual sales of approximately $152 million.
Teva's Venlafaxine HCl Tablets are the AB-rated generic equivalent of Wyeth's Effexor Tablets, a product indicated for the treatment of major depressive disorder.
The brand product has annual sales of approximately $152 million.
You May Also Be Interested In
- Teva Provides Updated 2012 Non-GAAP Financial Outlook; Updated 2012 Non-GAAP Diluted EPS of $5.30 to $5.40
- Dr. Reddy’s Labs (RDY) Launches Generic OTC Prevacid (NVS)
- Auxilium (AUXL) Files Suit Against Watson (WPI) Over Testim 1% Gel
Create E-mail Alert Related Categories
FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
